Sheepish about social networking

Letters From the Home Front

Want to see the future of Real Estate tech?
Limited seating available for ICSF Hacker Connect, July 17

I was reading this morning about a new obesity drug that has Wall Street analysts gravely disappointed. It seems that after years of clinical trials, the drug passed two of three important tests with flying colors. It helped lower cholesterol and, if that wasn’t enough, it didn’t appear to cause heart-valve failure. It sounds like a winner so far.

The one test it failed, however, was a doozy. The weight-loss drug did not result in people actually losing weight.